e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Therapeutic approaches in inflammatory lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Host defence peptide prodrugs are respirable when delivered by vibrating mesh nebuliser
Eanna Forde (Mayo, Ireland), Eanna Forde, Hilary Humphreys, Catherine Greene, Deirdre Fitzgerald-Hughes, Louise Sweeney, Ronan MacLoughlin, Marc Devocelle
Source:
International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Session:
Therapeutic approaches in inflammatory lung disease
Session type:
Thematic Poster Session
Number:
3888
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Eanna Forde (Mayo, Ireland), Eanna Forde, Hilary Humphreys, Catherine Greene, Deirdre Fitzgerald-Hughes, Louise Sweeney, Ronan MacLoughlin, Marc Devocelle. LATE-BREAKING ABSTRACT: Host defence peptide prodrugs are respirable when delivered by vibrating mesh nebuliser. Eur Respir J 2015; 46: Suppl. 59, 3888
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
LATE-BREAKING ABSTRACT: High expression of Midkine in the airways of patients with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
Neutrophil elastase-activated host defence peptide prodrugs kill
pseudomonas aeruginosa
in a cystic fibrosis lung milieu
Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases
Year: 2014
Airway surface liquid concentrations of aztreonam lysine for inhalation in children with cystic fibrosis: A modeling study
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
LATE-BREAKING ABSTRACT: Sweetening Antibiotic Treatment for Eradication of Bacteria Biofilm
Source: International Congress 2014 – Cystic fibrosis: assessment and treatment
Year: 2014
LATE-BREAKING ABSTRACT: Tomoscintigraphic comparison of lung deposition with a vibrating-mesh and a jet nebulizer
Source: International Congress 2015 – A more functional view of chest pathology
Year: 2015
LATE-BREAKING ABSTRACT: The differential pattern of deposition of nano-ranged particles in the airways of exposed workers
Source: International Congress 2015 – Occupational and environmental exposure assessment and biomarkers
Year: 2015
LATE-BREAKING ABSTRACT: Inhaled diesel exhaust alters immune response proteins in the bronchial secretome in humans
Source: International Congress 2016 – Role of genetics and exposures in COPD and asthma
Year: 2016
Targeting Antibiotics to Pseudomonas aeruginosa in Small airways (TAPAS) in patients with Cystic Fibrosis
Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects
Year: 2021
LATE-BREAKING ABSTRACT: Reducing inflammation in the lung by targeting the endothelial cystic fibrosis transmembrane conductance regulator with copper-tobramycin
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014
LATE-BREAKING ABSTRACT: Is there a relationship between use of inhaled antibiotics and prevalence of fungal isolates in the respiratory secretions of people with cystic fibrosis? A retrospective data analysis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015
Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
LATE-BREAKING ABSTRACT: Bacterial microbiota of mattress dust and nasal samples, farming exposure, and childhood asthma
Source: International Congress 2015 – Occupational and environmental exposure assessment and biomarkers
Year: 2015
Anaerobic bacteria and host defence in cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
LATE-BREAKING ABSTRACT: The use of in vitro Human Airway Epithelia for the development of novel antivirals against human rhinoviruses (HRV)
Source: International Congress 2014 – Respiratory infections in children
Year: 2014
Alternating inhaled antibiotic therapy in CF: A single center analysis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Histidinylated polylysines: An alternative antibacterial and fluidifying agent in cystic fibrosis.**
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015
Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
LATE-BREAKING ABSTRACT: Investigation of a novel small molecule furin inhibitor with regards Pseudomonas aeruginosa exotoxin A-induced cytotoxicity in human airways
Source: International Congress 2014 – Novel approaches in the management of lung transplant candidates and recipients
Year: 2014
Lung Clearance Index (LCI) and FEV
1
on the evaluation of the effect of tobramycin solution for inhalation (TIS) among patients with cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
LATE-BREAKING ABSTRACT: Complicated silicosis in an Australian worker from cutting engineered stone countertops: An embarrassing first for Australia
Source: International Congress 2015 – Occupational disease: clinical cases and series
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept